Leiden

• DISTINCT: inDividual, targeted thrombosIS prophylaxis versus the standard ‘one size fits all’ approach in patients undergoing Total hIp or t … Recruiting
  2023-510186-98-00 6 2024-10-23 Venous thromboembolism
• PERi-operative Selective Decontamination of the Digestive tract to prevent severe infectious complications after Esophagectomy: a Randomized … Recruiting
  2023-504144-33-01 11 2024-10-17 esophageal cancer
• MCA-derived MSC therapy in renal transplant recipients Recruiting
  2024-512553-25-00 3 2024-10-15 Rejection transplanted kidney
• DOSAgE study: A multicenter randomized phase III trial of DOSe-reduced Chemotherapy for Advanced Colorectal Cancer in Older patients Recruiting
  2023-506115-17-00 5 2024-10-14 Metastatic Colorectal Cancer
• Can we Save the rectum by watchful waiting or transanal surgery following short- or long-course radioTherapy and Additional local oR systemi … Recruiting
  2024-514620-17-00 4 2024-10-14 Patients with early-stage rectal cancer (defined as early rectal cance
• IDE196 (Darovasertib) in Combination with Crizotinib as First-line Therapy in Metastatic Uveal Melanoma Recruiting
  2023-506686-66-01 10 2024-10-09 HLA-A2 negative metastatic uveal melanoma
• Clinical trial comparing MK-2870 given with pembrolizumab to pembrolizumab alone in participants who have had surgery for NSCLC Recruiting
  2023-508012-35-00 5 2024-10-02 Newly diagnosed NSCLC with resectable clinical Stage II, IIIA or IIIB
• (NFPET) 89Zr-Bevacizumab PET/CT imaging in NF2 patients Recruiting
  2024-512860-75-00 4 2024-10-01 NF2-related schwannomatosis
• A lower dose olaparib, combined with a drug which inhibits olaparib degradation, to increase tolerability and decrease the price of the trea … Recruiting
  2024-516414-38-00 11 2024-10-01 Cancer
• Five-year boostability after single-visit single-dose intramuscular rabies pre-exposure prophylaxis Recruiting
  2023-510480-35-00 6 2024-09-19 viral infections
• Personalized dosing of FOLFIRINOX in pancreatic cancer patients: a phase-2 pharmacokinetic, safety and feasibility trial Recruiting
  2024-510576-21-00 4 2024-09-18 Pancreatic cancer
• A follow-up study to test long-term treatment with BI 1015550 in people with pulmonary fibrosis who took part in a previous study with BI 10 … Recruiting
  2023-507353-15-00 5 2024-09-10 idiopathic pulmonary fibrosis (IPF)
• A study of efgartigimod PH20 SC in children between 2 and less than 18 years of age with generalized myasthenia gravis Recruiting
  2023-506159-12-00 10 2024-09-06 Generalized Myasthenia Gravis
• The RED FLASH study Recruiting
  2023-507847-13-00 5 2024-08-09 Breast cancer
• A study of the safety and efficacy of MB-dNPM-1-TCR.1 in patients with relapsed or refractory AML. Recruiting
  2023-505806-41-00 7 2024-08-01 Acute myeloid leukemia
• SALVOVAR trial: A pragmatic randomized phase III trial to assess the utility of adjusting chemotherapy dose & dosing schedule with the SALVa … Recruiting
  2023-508260-30-01 5 2024-07-30 Patients with poor prognostic OVARian cancers based on the tumor prima
• OPTIMISE: Optimized Immunosuppression for Corneal Transplantation: a multi-centre randomized controlled clinical trial Recruiting
  2022-500109-41-00 6 2024-07-29 Corneal transplantation, Descemet's Membrane Endothelial Keratoplasty
• A long-term follow-up study for patients treated with Galapagos CAR T cell therapies Recruiting
  2023-510173-34-00 5 2024-07-26 Relapsed/refractory B-Cell non-Hodgkin lymphoma
• Study of RMC-6291 and RMC-6236 With Other Anti-Cancer Agents in Patients With RAS G12C-Mutated NSCLC - Subprotocol A Recruiting
  2023-509571-16-00 3 2024-07-17 Lung Cancer
• A study of RMC-6236 in combination with pembrolizumab in participants with nonsmall cell lung cancer with certain mutations -Subprotocol B Recruiting
  2023-509572-42-00 3 2024-07-17 Lung Cancer
• A first-in-human study of the safety of an immunosuppressive antibody (IMP761) in healthy volunteers. Recruiting
  2024-510761-42-00 1 2024-07-17 autoimmunity
• Phase 2 Study of HER3-DXd in Locally Advanced or Metastatic Solid Tumors Recruiting
  2023-507641-29-00 4 2024-07-15 Locally Advanced or Metastatic Solid Tumors
• A Phase 3 Study of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn (HDFN) Recruiting
  2022-502629-16-00 5 2024-07-10 Hemolytic Disease of the Fetus and Newborn (HDFN)
• Study of INBRX-109 in Patients with Advanced Solid Tumors, Including Sarcomas. Recruiting
  2023-508139-29-00 7 2024-06-26 Advanced or metastatic solid tumors

Showing 169–192 of 459 trials